Publication | Open Access
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
13
Citations
15
References
2024
Year
PURITY is registered at ClinicalTrials.gov (NCT06037980) and EuCT(2023-503295-25-00).
| Year | Citations | |
|---|---|---|
Page 1
Page 1